Collaborating to open up new frontiers
Beactica participates selectively in major European research initiatives. This enables the Company to be an active part in opening up new frontiers in the field as well as train the next generation of drug hunters - both essential to the future of the sector as well as Beactica’s growth.
Beactica participates in this initial training network (ITN) that aims to deliver 15 skilled early-stage researchers in the field of fragment-based lead discovery (FBLD). The FRAGNET network is composed of eight academic beneficiaries (VU University Amsterdam, University of York, Hungarian Academy of Sciences, Universitat de Barcelona), four industrial beneficiaries (Beactica, Novartis, Vernalis, Zobio) as well as five partner organizations (GSK, Roche, Servier, IOTA, 24 Media Labs). The FRAGNET project is active 2016–2019.
Beactica participates in this European research initiative to create a large drug discovery platform with the aim to identify novel gram negative antibacterial substances. The ENABLE project is active 2014–2020.
Beactica participated in this European expertise network that aimed at molecular analysis and dynamic modeling of synapse function. The perspective was to generate a blueprint for the discovery of novel pathways and targets that enable rational strategies to design therapies for human brain disease. The SynSys project was active 2010–2014.
Beactica participated in this initial training network, ITN, that buildt on our knowledge of genome information and that aims to develop a new generation of neuroscientists, contributing to the fight against brain disorders. The BrainTrain project was active 2011–2014.
Beactica participated in this collaborative large-scale integrating project with a role to discover new classes of drugs targetting Cys-loop receptors, a superfamily of ligand-gated ion channels. The NeuroCyprres project was active 2008–2012.